Pfizer Working To Resolve Sickle Cell Drug Hold Up, Dolsten Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Rivipansel, partnered with GlycoMimetics, is one of the most advanced drugs in Pfizer’s rare disease pipeline. Phase III studies have been delayed, however, due to a manufacturing issue impacting supply.
You may also be interested in...
FDA Patient Meeting On Huntington’s, Parkinson’s: No News Is Good News
Patient-focused drug development meetings address 'soft symptoms' and reimbursement challenges as FDA says it's familiar with most concerns aired by participants.
GlycoMimetics’ Sickle Cell Candidate Nearly Ready For Hand-Over To Pfizer
Biotech focused on role of carbohydrates in biological processes completes Phase II program of lead candidate for sickle cell disease. Under a 2011 partnership, Pfizer takes over development of GMI-1070 in Phase III.
The Orphan Drug Boom: Gold Rush Or Flash In The Pan?
Rare disease drug development has ballooned in just three years, powered by the success of independent biotechs like Alexion, Big Pharma’s entrée into the field, and pressure from regulators and payors that is dis-incentivizing development of traditional primary care drugs. The positive momentum has intensified dealmaking in the orphan drug space and is giving investors confidence to back rare disease-focused start-ups. Some have coined the resulting movement the “orphan drug bubble,” but interest isn’t likely to deflate soon – at least not as long as Big Pharma continues to invest in the area and industry is able to sustain a favorable reimbursement climate for ultra-premium-priced drugs.